Efficacy of Durvalumab for Early-Stage TNBC Examined by Race
In Phase I/II trial of durvalumab with neoadjuvant chemo, pathological complete response rates similar for Black, non-Black patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.